Aeolus Pharmaceuticals Inc. (OTCMKTS:AOLS) will be issuing its quarterly earnings data on Monday, August 14th.

Aeolus Pharmaceuticals (OTCMKTS:AOLS) last issued its quarterly earnings results on Monday, May 15th. The biopharmaceutical company reported ($0.01) EPS for the quarter. The business had revenue of $0.13 million for the quarter. Aeolus Pharmaceuticals had a negative net margin of 283.29% and a negative return on equity of 151.30%. On average, analysts expect Aeolus Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of Aeolus Pharmaceuticals Inc. (OTCMKTS AOLS) opened at 0.07264 on Monday. Aeolus Pharmaceuticals Inc. has a 12 month low of $0.05 and a 12 month high of $0.27. The stock’s market capitalization is $11.05 million. The company’s 50 day moving average price is $0.09 and its 200-day moving average price is $0.13.

COPYRIGHT VIOLATION NOTICE: This article was first reported by American Banking News and is owned by of American Banking News. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at

About Aeolus Pharmaceuticals

Aeolus Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on developing a platform of compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. As of September 30, 2016, the Company’s platform consisted of approximately 180 compounds licensed from the University of Colorado (UC), Duke University (Duke) and National Jewish Health (NJH).

Receive News & Ratings for Aeolus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeolus Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.